Advagene Biopharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-68.29	-69.42	-92.11	-118.38	-92.69	Upgrade
Depreciation & Amortization	2.19	2.18	5.86	6.4	7.03	Upgrade
Other Amortization	-	-	6.14	5.2	0.7	Upgrade
Loss (Gain) From Sale of Investments	-	-	-	-	-0.05	Upgrade
Other Operating Activities	-0.16	-0.16	-0.08	0.12	0.16	Upgrade
Change in Accounts Receivable	-	0.01	-	-	3.99	Upgrade
Change in Accounts Payable	3.74	-1.91	0.5	0.07	-4.31	Upgrade
Change in Other Net Operating Assets	-0.8	-1.35	2	-2.77	-3.66	Upgrade
Operating Cash Flow	-63.33	-70.65	-77.7	-109.35	-67.18	Upgrade
Capital Expenditures	-2.31	-0.48	-	-0.21	-0.52	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-10	-	Upgrade
Investment in Securities	70	-89.5	25	124.5	-79.5	Upgrade
Other Investing Activities	-	-0.01	1.5	-	-1.5	Upgrade
Investing Cash Flow	67.7	-89.99	26.5	114.29	-81.52	Upgrade
Long-Term Debt Repaid	-1.85	-1.74	-1.93	-1.83	-1.79	Upgrade
Net Debt Issued (Repaid)	-1.85	-1.74	-1.93	-1.83	-1.79	Upgrade
Issuance of Common Stock	-	150	100.31	0.57	42.93	Upgrade
Financing Cash Flow	-1.85	148.26	98.38	-1.26	41.14	Upgrade
Net Cash Flow	2.52	-12.38	47.18	3.67	-107.56	Upgrade
Free Cash Flow	-65.64	-71.12	-77.7	-109.56	-67.7	Upgrade
Free Cash Flow Per Share	-1.10	-1.30	-1.54	-2.22	-1.39	Upgrade
Cash Interest Paid	0.18	0.15	0.04	0.08	0.13	Upgrade
Cash Income Tax Paid	0.16	0.16	0.08	-0.12	-0.16	Upgrade
Levered Free Cash Flow	-41.78	-46.06	-43.87	-76.12	-55.71	Upgrade
Unlevered Free Cash Flow	-41.67	-45.96	-43.85	-76.07	-55.63	Upgrade
Change in Working Capital	2.93	-3.25	2.5	-2.7	17.68	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.